SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: HB who wrote (150)2/3/1998 2:54:00 PM
From: Thomas M.  Read Replies (1) | Respond to of 523
 
I can bring life to the thread . . . How about that Kobe Bryant kid! -g- The fact that the stock did not drift down after the Big Kahuna is a huge positive. The fact that Michael Burke and Mark Lampert still love it is great. Given Pfizer's history of decidedly thorough Phase I trials, NRGN will likely double from here if anything ever gets to Phase II. Interestingly, all of my biotechs have perked up, even thought the BTK is fairly dormant.

Tom


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News